Q-omics provides the consensus-scored RDX profile across patient tissues and cancer cell-line models. RDX expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RDX is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RDX RNA expression shows 20,946 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where RDX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDX survival associations across molecular data types. RDX RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDX RNA expression–survival associations across cancer types. High RDX expression shows unfavorable associations in BLCA, UVM, LGG, LUAD and CESC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RDX RNA expression.
This table summarizes RDX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RDX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDX shows lower tumor expression in THCA, LUSC, LUAD, BRCA and KICH and higher tumor expression in HNSC. The HNSC box plot shows higher RDX RNA expression in tumor versus normal tissue (log2 FC = +1.433, t-test p < 0.001).
This table shows molecular features associated with RDX in patient tissues and cancer cell lines. In patient samples, RDX shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RDX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
